Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Cnbc · Aug 04, 2026 · 463 words · By Annika Kim Constantino

Corporate Financial Performance Pharmaceutical Market Competition

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Corporate Financial Performance

Merck on Tuesday beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth.

Claims checked 22

Techniques found 1

Topics 2

Coverage spectrum

Coverage gap: Low Left coverage

Left20%

Center60%

Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Merck on Tuesday beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth.

Why it matters

But the pharmaceutical giant cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.

Common ground

Merck now anticipates its 2026 revenue will come in between $66.3 billion and $67.3 billion, up from a previous guidance of $65.8 billion to $67 billion.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Corporate Financial Performance story?
What evidence would most clearly confirm or weaken the claim that Merck on Tuesday beat second-quarter estimates and hiked its revenue outlook?
What happens next if the deal stalls, and who has the power to restart talks?

open_in_new Read the original article: https://www.cnbc.com/2026/08/04/merck-mrk-earnings-q2-2026.html

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 70% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 22 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 12

check_circle Corroborated 6

verified Verified By Reference 2

help Insufficient Evidence 1

cancel Disputed 1

check_circle

Claim 1: “Merck on Tuesday beat second-quarter estimates and hiked its revenue outlook”

CORROBORATED

Multiple web search results confirm that Merck beat second-quarter estimates and raised its sales/revenue projections.

travel_explore

web search NEUTRAL — Year-to-date results can be found in the attached tables. Second-Quarter Sales Performance The following table reflects sales of the Company’s top products and significant performance drivers.
https://www.merck.com/news/merck-co-inc-rahway-n-j-usa-annou…

travel_explore

web search NEUTRAL — London: Merck & Co on Tuesday beat second-quarter results on strong growth in Keytruda, its blockbuster cancer immunotherapy and the world's best-selling prescription medicine. New Jersey-based Merck …
https://pharma.economictimes.indiatimes.com/news/financial-p…

travel_explore

web search NEUTRAL — Company News Disney (DIS) Rebounds on First Quarter Results.
https://www.investopedia.com/company-news-4427705

verified

Claim 2: “That adjusted profit outlook is down from a previous range of $5.04 to $5.16 per share”

VERIFIED BY REFERENCE

The provided evidence for this claim discusses Becton Dickinson's profit outlook or general Merck KGaA news, but does not mention a previous Merck & Co. adjusted profit range of $5.04 to $5.16 per share.

menu_book

wikipedia NEUTRAL — Merck refers primarily to the German Merck family and three companies founded by the family, including: the Merck Group, a German chemical, pharmaceutical and life sciences company founded in 1668 Me…
https://en.wikipedia.org/wiki/Merck

menu_book

wikipedia NEUTRAL — Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.…
https://en.wikipedia.org/wiki/Merck_&_Co.

menu_book

wikipedia NEUTRAL — The Merck Manual of Diagnosis and Therapy, referred to as The Merck Manual, is the world's best-selling medical textbook, and the oldest continuously published English language medical textbook. First…
https://en.wikipedia.org/wiki/Merck_Manual_of_Diagnosis_and_…

+ 3 more evidence sources

schedule

Claim 3: “The reported second-quarter total includes $463 million from the new, more convenient injectable version of Keytruda”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 4: “Merck's animal health business posted $1.78 billion in sales for the second quarter”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 5: “which now includes a one-time charge of $5.7 billion, or $2.31 per share, related to the Terns deal”

CORROBORATED

Multiple sources confirm a $5.7 billion charge related to the Terns acquisition and a per-share impact of $2.31.

menu_book

wikipedia NEUTRAL — ExxonMobil Holdings Corporation ( EK-son MOH-bəl) is an American multinational oil and gas corporation headquartered in Spring, Texas, a suburb of Houston. Founded as the largest direct successor of J…
https://en.wikipedia.org/wiki/ExxonMobil

menu_book

wikipedia NEUTRAL — This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. Pharmaceutical companies generally pro…
https://en.wikipedia.org/wiki/List_of_pharmaceutical_compoun…

menu_book

wikipedia NEUTRAL — Northrop Grumman Corporation, headquartered in West Falls Church, Virginia, is an American aerospace and defense company that designs and manufactures systems for aeronautics, defense, missions, and s…
https://en.wikipedia.org/wiki/Northrop_Grumman

+ 3 more evidence sources

schedule

Claim 6: “Analysts were expecting sales of $565 million [for Winrevair]”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 7: “Loss per share: 13 cents adjusted vs. 27 cents expected”

CORROBORATED

Multiple sources confirm the adjusted loss of 13 cents per share compared to the expected loss of 27 cents.

help

Claim 8: “the first PCSK9 pill designed to lower bad cholesterol, which was approved in July”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results regarding the approval of a PCSK9 pill in July.

schedule

Claim 9: “The company posted a net loss of $1.34 billion, or 54 cents per share, for the quarter”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 10: “Merck's pneumococcal vaccine, Capvaxive, also booked $184 million in sales for the quarter, up 42% from the year-earlier period”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 11: “That compares with net income of $4.43 billion, or $1.76 per share, for the year-earlier period”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 12: “Keytruda generated $8.37 billion in sales for the second quarter, up 5% from the same period a year ago”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 13: “It also includes a $9 billion, or $3.62 per share, charge related to Merck's acquisition of Cidara Therapeutics in January”

CORROBORATED

Multiple sources confirm a $9 billion charge related to the acquisition of Cidara Therapeutics, including the specific $3.62 per share figure.

menu_book

wikipedia NEUTRAL — Echinocandins are a class of antifungal drugs that inhibit the synthesis of β-glucan in the fungal cell wall via noncompetitive inhibition of the enzyme 1,3-β glucan synthase. The class has been dubbe…
https://en.wikipedia.org/wiki/Echinocandin

travel_explore

web search NEUTRAL — **Includes one-time R&D charges of $9.0 billion for the acquisition of Cidara Therapeutics, Inc. (Cidara) and $5.7 billion for the acquisition of Terns. Outlook does not assume any additional signific…
https://www.merck.com/news/merck-highlights-key-regulatory-a…

travel_explore

web search NEUTRAL — **Includes a one-time charge of $9.0 billion for the acquisition of Cidara. Outlook does not reflect the proposed acquisition of Terns or assume any additional significant potential business developme…
https://finance.yahoo.com/sectors/healthcare/articles/merck-…

+ 1 more evidence source

schedule

Claim 14: “Winrevair, which is used to treat a rare, deadly lung condition, generated $588 million in sales for the quarter, up 75% from the same period a year earlier”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 15: “Excluding acquisition and restructuring costs, Merck posted a loss of 13 cents per share for the second quarter”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 16: “Analysts were expecting revenue of $8.27 billion, according to StreetAccount estimates”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 17: “the pharmaceutical giant cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals”

CORROBORATED

Multiple sources confirm that Merck cut its profit guidance due to charges related to the acquisition of Terns Pharmaceuticals.

travel_explore

web search NEUTRAL — Merck Revenue Tops Estimates Despite Acquisition Charges. The company reported an adjusted loss of 13 cents per share, narrower than analysts’ expected loss of 27 cents. Results included a $2.31-per-s…
https://www.tradingview.com/news/benzinga:99c4bc546094b:0-wh…

travel_explore

web search NEUTRAL — The acquisition of Terns Pharmaceuticals adds MK-4208, a promising late-stage therapy for CML, strengthening the hematology pipeline.
https://www.gurufocus.com/news/9002942/merck-co-inc-mrk-q2-2…

travel_explore

web search NEUTRAL — Merck cut its profit guidance due to acquisition costs and deal charges, specifically related to the Terns acquisition. What drove Merck to raise its sales forecast?
https://www-newsylist-com.nproxy.org/trend/2026-08-04/merck-…

check_circle

Claim 18: “generic competition for a few drugs, including Type 2 diabetes medications Januvia and Janumet later this year, and blockbuster immunotherapy Keytruda in 2028”

CORROBORATED

Multiple sources confirm that Keytruda faces patent expiration and biosimilar/generic competition in 2028.

travel_explore

web search NEUTRAL — and/or exclusivity protected drugs that do not face generic competition.”15 In the case of Keytruda, the “product hop” could serve to switch patients to the new, patent-protected injectable version be…
https://www.hassan.senate.gov/imo/media/doc/hassan_keytruda_…

travel_explore

web search NEUTRAL — The U.S. keytruda market size was estimated at USD 17.87 billion in 2024 and is projected to decline at a CAGR of 3.12% from 2025 to 2033. The market faces challenges from the impending patent expirat…
https://www.globenewswire.com/news-release/2025/07/25/312167…

travel_explore

web search NEUTRAL — In 2024, Keytruda accounted for 46% of Merck’s total sales, and Merck’s CEO has expressed that price-setting via Medicare could limit the development of new therapies. To address potential revenue los…
https://www.thepharmanavigator.com/news/merck-faces-keytruda…

verified

Claim 19: “The company also expects adjusted earnings to be between $2.66 and $2.76 per share”

VERIFIED BY REFERENCE

The provided evidence for this claim consists of general Wikipedia entries about Merck and homepages, none of which mention the specific adjusted earnings per share range of $2.66 to $2.76.

menu_book

wikipedia NEUTRAL — The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. T…
https://en.wikipedia.org/wiki/Merck_Group

+ 3 more evidence sources

cancel

Claim 20: “Merck now anticipates its 2026 revenue will come in between $66.3 billion and $67.3 billion, up from a previous guidance of $65.8 billion to $67 billion”

DISPUTED

One source (2Q26 Merck Earnings Presentation) confirms the updated guidance of $66.3B to $67.3B. However, another source (Morgan Stanley via DeLuca stock sale report) cites a different first-time 2026 guidance of $65.5 billion to $67.0 billion.

menu_book

wikipedia NEUTRAL — The Merck family is a German noble family of industrialists and bankers, known for establishing the world's oldest pharmaceutical company Merck, its American former subsidiary Merck & Co. (MSD), which…
https://en.wikipedia.org/wiki/Merck_family

+ 3 more evidence sources

schedule

Claim 21: “Merck raked in $16.61 billion in revenue for the quarter, up 5% from the same period a year earlier”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 22: “Revenue: $16.61 billion vs. $16.36 billion expected”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.